TNDM Stock Tandem Diabetes Care, Inc.
STRONG BUY US · NasdaqGMNew coverage and improving sentiment can support a rebound if execution stabilizes.
Future value: $27.76 (+46.89%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Fresh analyst initiation and improving momentum.
- ▸Above 50-day MA (+3.25%)
- ▸Volume 2.14× average — accumulation
- ▸~47% upside to price target
Is TNDM a buy right now?
Trend: TNDM is trading above the 50-day average (+3.22%), RSI 61 — neutral momentum, with a 3-month return of +6.42%.
Valuation & quality: Tandem Diabetes Care, Inc. trades on forward P/E 118.9, price-to-book 10.08; fundamentals show net margin -6.1%, return on equity -48.0%, revenue growth 5.8% year on year.
Analyst consensus: 21 analysts have a mean 12-month price target of $27.76 (+46.9% vs the last close; range $18.00 – $50.00), consensus rating “buy”.
Our screen: STRONG BUY (score 4) — New coverage and improving sentiment can support a rebound if execution stabilizes.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -24.20% | +1.80% | -11.90% | -12.30% | +29.20% | +12.90% | -25.90% | +15.90% |
Fundamentals
Analyst price target
Technical signals
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system.
Sector: Healthcare · Industry: Medical Devices · United States · 2,500 employees · Website
Related Biotech picks
Browse: all US stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.